AUTHOR=Zhu Lin , Zhang Hairong , Zhang Xiaoyu , Chen Ruoqing , Xia Lei 

TITLE=Drug repositioning and ovarian cancer, a study based on Mendelian randomisation analysis

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1376515

DOI=10.3389/fonc.2024.1376515

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>The role of drug repositioning in the treatment of ovarian cancer has received increasing attention. Although promising results have been achieved, there are also major controversies.</p></sec><sec><title>Methods</title><p>In this study, we conducted a drug-target Mendelian randomisation (MR) analysis to systematically investigate the reported effects and relevance of traditional drugs in the treatment of ovarian cancer. The inverse-variance weighted (IVW) method was used in the main analysis to estimate the causal effect. Several MR methods were used simultaneously to test the robustness of the results.</p></sec><sec><title>Results</title><p>By screening 31 drugs with 110 targets, FNTA, HSPA5, NEU1, CCND1, CASP1, CASP3 were negatively correlated with ovarian cancer, and HMGCR, PLA2G4A, ITGAL, PTGS1, FNTB were positively correlated with ovarian cancer.</p></sec><sec><title>Conclusion</title><p>Statins (HMGCR blockers), lonafarnib (farnesyltransferase inhibitors), the anti-inflammatory drug aspirin, and the anti-malarial drug adiponectin all have potential therapeutic roles in ovarian cancer treatment.</p></sec>